WCM Investment Management LLC Lowers Position in Novo Nordisk A/S $NVO

WCM Investment Management LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 67.7% during the 1st quarter, Holdings Channel.com reports. The firm owned 810,997 shares of the company’s stock after selling 1,697,295 shares during the period. WCM Investment Management LLC’s holdings in Novo Nordisk A/S were worth $28,620,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Godfrey Financial Associates Inc. purchased a new position in Novo Nordisk A/S during the 4th quarter valued at about $25,000. Scarborough Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the first quarter worth $26,000. WealthCollab LLC increased its holdings in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares in the last quarter. American National Bank & Trust purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth about $28,000. Finally, Maseco LLP bought a new position in Novo Nordisk A/S in the 4th quarter worth about $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.1%

NVO stock opened at $50.29 on Monday. The company has a market cap of $224.56 billion, a price-to-earnings ratio of 11.81, a P/E/G ratio of 4.59 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The business’s 50-day moving average is $46.09 and its two-hundred day moving average is $45.79. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $71.79.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion during the quarter. As a group, analysts forecast that Novo Nordisk A/S will post 3.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Wolfe Research initiated coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating for the company. Finally, Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Five equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: India approved Wegovy for treating MASH, expanding the drug’s potential beyond obesity into fatty liver disease and opening another large growth opportunity. Reuters article
• Positive Sentiment: Novo launched oral Wegovy in Europe after winning European Commission approval, giving it the first GLP-1 pill for weight management in the region and strengthening its first-mover advantage. Yahoo Finance article
• Positive Sentiment: Reuters reported Novo will launch a lower-cost authorized copy of Ozempic in South Africa, a move that could expand access and support volume growth in an important emerging market. Reuters article
• Neutral Sentiment: Analysts at Erste Group trimmed FY2026 EPS estimates slightly to $3.22 from $3.23, a minor cut that does not materially change the current outlook but signals some caution. MarketBeat article
• Neutral Sentiment: Brokerages continue to rate Novo Nordisk around “Hold,” suggesting the recent rally is being met with a more balanced valuation view. American Banking News article
• Negative Sentiment: Some commentary notes that Eli Lilly still has a chance to win parts of the GLP-1 market, highlighting competitive risk even as Novo’s pill gains traction. The Motley Fool article

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.